NL-OMON26185招募中不适用
Adalimumab drug optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trail
Reade Rheumatology Research Institute0 个研究点目标入组 267 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 267
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria;
- •Starting adalimumab as the first biological therapy
- •Who has agreed to participate (written informed consent);
- •Age 18 years or older.
排除标准
- •Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation;
- •Life expectancy shorter than follow-up period of the study;
- •Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.
研究者
相似试验
进行中（未招募）
1 期
Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood (ADDORA): multi-center open label randomizedcontrolled trailRheumatoid arthritisEUCTR2019-001554-25-NLReade267
招募中
不适用
Adalimumab dose optimisation in rheumatoid arthritis using therapeutic drug monitoring (ADDORA): multi-centre open label randomised controlled trailrheumatoid arthritisNL-OMON47985Jan van Breemen Instituut267
进行中（未招募）
1 期
Adalimumab in rheumatoid arthritis. An investigation of changes in disease activity and course of joint destruction by use of 3 Tesla Whole-Body MRI, dedicated 3 Tesla MRI and CT of the hand, and soluble biomarkers.Whole-Body MRI in Rheumatoid Arthritis Protocol (WRAP)Reumatoid artritisMedDRA version: 12.1Level: LLTClassification code 10003268Term: Arthritis rheumatoidEUCTR2009-014394-41-DKHvidovre Hospital
招募中
4 期
Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug MonitoringRheumatoid ArthritisNCT04194827Reade Rheumatology Research Institute267
已完成
4 期
Predictors of the Response to Adalimumab in Rheumatoid ArthritisRheumatoid ArthritisNCT00234234University Hospital, Rouen200